ADMA Biologics is a U.S.-based biopharmaceutical company that manufactures and markets specialty immune globulin products for patients with immunodeficiencies and infectious disease risks. The company operates two main segments: ADMA BioManufacturing, which produces three FDA-approved immune globulin products—ASCENIV and BIVIGAM for primary immunodeficiency treatment and Nabi-HB for hepatitis B exposure—as well as a pipeline hyperimmune globulin candidate; and ADMA BioCenters, which operates plasma collection facilities that source plasma for the company's manufacturing while generating revenue from third-party plasma sales and contract services. The company generates revenue by selling its approved products through distributors, specialty pharmacies, and home health providers serving approximately 500 leading specialty programs, as well as through royalties from an exclusive European license agreement, third-party plasma sales, and contract manufacturing services.